Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 47.26% | 12.32% | -473.86% | -278.88% | -219.76% |
| Total Depreciation and Amortization | -30.06% | -53.00% | -70.77% | -78.50% | -78.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -103.50% | -8.67% | 246.56% | 279.61% | 324.84% |
| Change in Net Operating Assets | -160.52% | -112.95% | -99.15% | -43.05% | -22.30% |
| Cash from Operations | -244.02% | -192.84% | -121.32% | -60.97% | -48.84% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,755.36% | -2,670.76% | -259.40% | -663.57% | -151.72% |
| Cash from Investing | -1,031.84% | -303.30% | 60.99% | 80.68% | 66.31% |
| Total Debt Issued | -- | -106.42% | -- | -- | 2,985.47% |
| Total Debt Repaid | 10.83% | 84.24% | 92.19% | 95.22% | 92.47% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 47.64% | -121.85% | -- | -102.78% |
| Cash from Financing | 96.04% | 51.48% | 78.31% | 53.22% | 10.71% |
| Foreign Exchange rate Adjustments | -102.16% | -102.43% | 183.28% | 195.04% | -22.68% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -848.59% | -345.84% | 31.04% | 74.24% | -0.43% |